Abbott Laboratories $ABT Position Increased by IFM Investors Pty Ltd

Key Points

• IFM Investors Pty Ltd increased its stake in Abbott Laboratories by 4.0%, acquiring an additional 12,889 shares, bringing its total holdings to 338,749 shares valued at $46,073,000.
• Wall Street analysts have mixed ratings on Abbott Laboratories, with an average target price of $145.22, as two analysts rate it a Strong Buy and sixteen give it a Buy or Hold rating.
• Abbott Laboratories reported earnings of $1.26 EPS for the quarter, meeting analysts' expectations, and its revenue rose by 7.4% year-over-year, amounting to $11.14 billion.

IFM Investors Pty Ltd lifted its position in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 4.0% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 338,749 shares of the healthcare product maker's stock after acquiring an additional 12,889 shares during the period. IFM Investors Pty Ltd's holdings in Abbott Laboratories were worth $46,073,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of ABT. Brighton Jones LLC grew its position in Abbott Laboratories by 10.1% in the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker's stock valued at $5,850,000 after buying an additional 4,755 shares in the last quarter. Bank Pictet & Cie Europe AG boosted its position in shares of Abbott Laboratories by 1.9% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 152,719 shares of the healthcare product maker's stock valued at $17,274,000 after purchasing an additional 2,774 shares in the last quarter. Woodline Partners LP bought a new position in shares of Abbott Laboratories during the 4th quarter valued at about $5,997,000. Novem Group purchased a new stake in Abbott Laboratories during the fourth quarter valued at about $251,000. Finally, 49 Wealth Management LLC boosted its holdings in shares of Abbott Laboratories by 8.8% in the fourth quarter. 49 Wealth Management LLC now owns 4,034 shares of the healthcare product maker's stock worth $456,000 after buying an additional 326 shares during the period. Institutional investors own 75.18% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Raymond James Financial reduced their price target on shares of Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating for the company in a research report on Friday, July 18th. Leerink Partnrs raised shares of Abbott Laboratories to a "hold" rating in a research report on Monday, June 16th. Mizuho raised their price objective on shares of Abbott Laboratories from $130.00 to $140.00 and gave the company a "neutral" rating in a research report on Wednesday, July 16th. BTIG Research lowered their price target on Abbott Laboratories from $148.00 to $145.00 and set a "buy" rating on the stock in a report on Friday, July 18th. Finally, Morgan Stanley lifted their price target on shares of Abbott Laboratories from $127.00 to $137.00 and gave the stock an "equal weight" rating in a research note on Tuesday, July 15th. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $145.22.

Insiders Place Their Bets

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the company's stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $134.55, for a total transaction of $746,752.50. Following the completion of the transaction, the chief financial officer owned 51,003 shares of the company's stock, valued at $6,862,453.65. This represents a 9.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.46% of the stock is currently owned by company insiders.

Abbott Laboratories Price Performance

Shares of ABT stock opened at $134.67 on Friday. The stock has a 50-day moving average price of $130.38 and a 200 day moving average price of $131.20. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25. The firm has a market cap of $234.39 billion, a price-to-earnings ratio of 16.88, a PEG ratio of 2.54 and a beta of 0.69. Abbott Laboratories has a 12 month low of $110.86 and a 12 month high of $141.23.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.26. The company had revenue of $11.14 billion during the quarter, compared to analyst estimates of $11.01 billion. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The company's revenue for the quarter was up 7.4% compared to the same quarter last year. During the same period in the previous year, the company earned $1.14 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Research analysts expect that Abbott Laboratories will post 5.14 EPS for the current year.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.